Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 21.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,555,555 shares of the company’s stock after purchasing an additional 1,150,000 shares during the quarter. Structure Therapeutics accounts for about 4.4% of Avoro Capital Advisors LLC’s holdings, making the stock its 8th largest holding. Avoro Capital Advisors LLC owned 9.25% of Structure Therapeutics worth $455,939,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. CWM LLC raised its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. State of Wyoming acquired a new position in Structure Therapeutics in the 2nd quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics in the 4th quarter worth about $127,000. Finally, Banque Cantonale Vaudoise acquired a new position in Structure Therapeutics in the 4th quarter worth about $205,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

GPCR stock opened at $42.91 on Wednesday. The business has a 50 day simple moving average of $43.22 and a 200-day simple moving average of $57.45. The firm has a market capitalization of $3.05 billion, a PE ratio of -49.32 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citizens Jmp reduced their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a report on Friday, February 27th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wolfe Research started coverage on Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.